Evidence map›Paper›PMID 34232734›Full record

ArticleJournal of virology2021

Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells.

Noam Erez, Linda S Wyatt, Jeffrey L Americo, Wei Xiao, Bernard Moss

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Noam Erez *Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.
Linda S Wyatt *Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.
Jeffrey L AmericoLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.
Wei XiaoLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.
Bernard MossLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healthgrid.94365.3d, Bethesda, Maryland, USA.ORCID 0000-0002-2154-8564
National Institutes of Health · US

Funding

Recombinant Virus VaccinesZIAAI000416 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOSS, BERNARD · 2009 to 2025
$17.3M
Poxvirus Gene Expression and DNA ReplicationZIAAI000307 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOSS, BERNARD · 2009 to 2025
$14.6M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)
6 · The paper itself

Abstract

Modified vaccinia virus Ankara (MVA) was derived by repeated passaging in chick fibroblasts, during which deletions and mutations rendered the virus unable to replicate in most mammalian cells. Marker rescue experiments demonstrated that the host range defect could be overcome by replacing DNA that had been deleted from near the left end of the genome. One virus isolate, however, recovered the ability to replicate in monkey BS-C-1 cells but not human cells without added DNA, suggesting that it arose from a spontaneous mutation. Here, we showed that variants with enhanced ability to replicate in BS-C-1 cells could be isolated by blind passaging of MVA and that in each there was a point mutation leading to an amino acid substitution in the D10 decapping enzyme. The sufficiency of these single mutations to enhance host range was confirmed by constructing recombinant viruses. The D10 mutations occurred at N- or C-terminal locations distal to the active site, suggesting an indirect effect on decapping or on another previously unknown role of D10. Although increased amounts of viral mRNA and proteins were found in BS-C-1 cells infected with the mutants compared to those with parental MVA, the increases were much less than the 1- to 2-log-higher virus yields. Nevertheless, a contributing role for diminished decapping in overcoming the host range defect was consistent with increased replication and viral protein synthesis in BS-C-1 cells infected with an MVA engineered to have active-site mutations that abrogate decapping activity entirely. Optimal decapping may vary depending on the biological context.

Indexed as

AnimalsCatalytic DomainCell LineChick EmbryoChlorocebus aethiopsHomologous RecombinationHost SpecificityHumansNucleotidasesOpen Reading FramesPoint MutationRNA, MessengerRNA, ViralSequence DeletionVaccinia virusViral Plaque AssayD10 protein, vaccinia virusNucleotidasesRNA, MessengerRNA, ViralViral Proteinsadaptive mutationsattenuated vaccinemRNA decappingMVApoxvirusvaccinia virusvirus-host interactionsvirus host range

Identifiers

PMID34232734
PMCPMC8428383
OpenAlexW3183053302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.